Chapters 39–46. The central therapeutic tension of ECMO: circuit patency versus patient bleeding.
# | Chapter | Core question it answers |
39 | ECMO Coagulation Physiology | What does blood do when it meets a foreign surface? |
40 | Unfractionated Heparin | Dosing, targets and the limits of the default agent. |
41 | Bivalirudin and Alternative Anticoagulants | When is a direct thrombin inhibitor the better choice? |
42 | Anticoagulation Monitoring | ACT, aPTT, anti-Xa, viscoelastic testing — which, and why they disagree. |
43 | Heparin Resistance and Antithrombin | The target is not reached — what is actually going on? |
44 | Heparin-Induced Thrombocytopenia | Recognition and management on a heparin-coated circuit. |
45 | Bleeding Management | Stopping the bleed without losing the circuit. |
46 | Transfusion Strategy | What thresholds are defensible, and on what evidence? |